The goal of this observational study is to evaluate the efficacy and tolerability of asciminib in real-life in patients with chronic myeloid leukemia treated in second or subsequent lines. The main object of the study is to assess the achievement of Major Molecular Response.
Patients aged ≥ 18 years and no upper age limit;
Patients with a diagnosis of CML-CP who started treatment with asciminib according to clinical practice - from the date of commercial availability of asciminib - until the end of recruitment period (two years after the first patient included);
Patients treated with asciminib in second or subsequent lines of therapy (≥2L)
Patients who provide written informed consent to participate in the study (if applicable).
None